Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin, Pär; Vickers, Andrew J; Sjoberg, Daniel D; Johansson, Robert; Granfors, Torvald; Johansson, Mattias; Pettersson, Kim; Scardino, Peter T; Hallmans, Göran; Lilja, Hans

Published in:
European Urology

DOI:
10.1016/j.eururo.2015.01.009

2015

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 24. Dec. 2018
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study

Pär Stattin\textsuperscript{a}, Andrew J. Vickers\textsuperscript{b}, Daniel D. Sjöberg\textsuperscript{b}, Robert Johansson\textsuperscript{c}, Torvald Granfors\textsuperscript{d}, Mattias Johansson\textsuperscript{e}, Kim Pettersson\textsuperscript{f}, Peter T. Scardino\textsuperscript{g}, Göran Hallman\textsuperscript{h}, Hans Lilja\textsuperscript{g,i,j,k,*}

\textsuperscript{a}Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden; \textsuperscript{b}Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; \textsuperscript{c}Regional Cancer Centre, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden; \textsuperscript{d}Department of Urology, Sankt Göran Hospital, Stockholm, Sweden; \textsuperscript{e}Section of Genetics, The International Agency for Research on Cancer, Lyon, France; \textsuperscript{f}Division of Biotechnology, University of Turku, Turku, Finland; \textsuperscript{g}Department of Surgery (Urology), Memorial Sloan Kettering Cancer Center, New York, NY, USA; \textsuperscript{h}Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden; \textsuperscript{i}Departments of Laboratory Medicine and Medical Science, Karolinska Institutet, Stockholm, Sweden; \textsuperscript{j}Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK; \textsuperscript{k}Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden

\textbf{Abstract}

\textbf{Background:} A disadvantage of prostate-specific antigen (PSA) for the early detection of prostate cancer (PCa) is that many men must be screened, biopsied, and diagnosed to prevent one death.

\textbf{Objective:} To increase the specificity of screening for lethal PCa at an early stage.

\textbf{Design, setting, and participants:} We conducted a case–control study nested within a population-based cohort. PSA and three additional kallikreins were measured in cryopreserved blood from a population-based cohort in Västerbotten, Sweden. Of 40,379 men providing blood at ages 40, 50, and 60 yr from 1986 to 2009, 12,542 men were followed for > 15 yr. From this cohort, the Swedish Cancer Registry identified 1,423 incident PCa cases, 235 with distant metastasis.

\textbf{Outcome measurements and statistical analysis:} Risk of distant metastasis for different PSA levels and a prespecified statistical model based on the four kallikrein markers.

\textbf{Results and limitations:} Most metastatic cases occurred in men with PSA in the top quartile at age 50 yr (69%) or 60 yr (74%), whereas 20-yr risk of metastasis for men with PSA below median was low (≤ 0.6%). Among men with PSA > 2 ng/ml, a prespecified model based on four kallikrein markers significantly enhanced the prediction of metastasis compared with PSA alone. About half of all men with PSA > 2 ng/ml were defined as low risk by this model and had a ≤ 1% 15-yr risk of metastasis.

\textbf{Conclusions:} Screening at ages 50–60 yr should focus on men with PSA in the top quartile. A marker panel can aid biopsy decision making.

\textbf{Patient summary:} For men in their fifties, screening should focus on those in the top 10% to 25% of PSA values because the majority of subsequent cases of distant metastasis are found among these men. Testing of four kallikrein markers in men with an elevated PSA could aid biopsy decision making.
1. Introduction

Recent evidence from randomized trials provides clear evidence that screening for prostate cancer (PCA) by testing serum levels of prostate-specific antigen (PSA) reduces cancer-specific mortality in men who would not otherwise be screened [1,2]. However, PSA is not specific to lethal PCAs. As a result, many men need to be screened, biopsied, and diagnosed to prevent one death. One estimate is that 781 men need to be screened and 27 diagnosed per PCA death avoided at 13 yr [1].

One way to change the harm-to-benefit ratio would be to screen for cancers that are destined to become lethal. Metastatic PCAs are associated with severe disease morbidity and a very high risk of PCa-specific death. We tested the hypothesis that PSA and a panel of PSA-related markers could predict the long-term risk of metastatic PCAs in a large representative population-based longitudinal study of men providing cryopreserved blood at ages 40, 50, and 60 yr from 1986 to 2009.

2. Patients and methods

2.1. Study population

The Va¨sterbotten Intervention Project (VIP) [3] is an ongoing population-based cohort study initiated in 1986 in which residents of Va¨sterbotten County, Sweden, are invited to receive a health examination at ages 40, 50, and 60 yr with blood drawn for cryopreservation. By January 2009, VIP included data on 40 379 unique men with 50 557 blood draws, representing >57% of the total background population [4]. Initially the rate of PSA testing in this population was low, but it has increased over recent years: The proportion of PCAs cases for which opportunistic screening was the cause for work-up leading to diagnosis increased from 9% in 2000 to 26% in 2005 and to 38% in 2011 [5]. However, these recent changes are likely to have little impact on metastasis rates in our current cohort due to the long lead time between diagnosis and metastasis.

2.2. Case identification and outcomes

In January 2009, the VIP cohort was linked to the Northern Sweden Regional Cancer Registry, part of the Swedish Cancer Registry, using the Swedish personal identity number. We identified 1423 incident PCa cases in the VIP cohort, 1377 of which had cryopreserved blood available for analysis. Clinical data were retrieved from the National Prostate Cancer Register. We reviewed hospital medical charts of men diagnosed with cancer to identify men who later had documented evidence of metastatic disease (ie, a positive bone scan) during the follow-up period. There were 126 patients with metastatic PCAs diagnosed during follow-up who subsequently died from PCAs, according to the Cause of Death Registry. Cause of death was assessed by medical chart review or, when charts were not available (n = 4), the Swedish Cause of Death Registry. An additional 12 men who died of PCa but who had not had metastases diagnosed prior to death were considered to have had metastatic disease at the date of death.

2.3. Control selection

Separate case-control matches were conducted for each end point: PCA diagnosis, PCA metastases, and PCA-specific death. There were separate analyses for men aged 40, 50, and 60 yr at baseline. For each relevant end point, we randomly selected three controls who were alive and event free at the date of the pertinent event for the index case, were within 3 mo of age of the index case, and had provided a blood sample within 3 mo of the blood draw for the index case. For the end point of PCAspecific death, all cases were matched successfully to three controls; for PCA metastases and PCA diagnosis, we expanded the window in 1-mo increments to 12 mo until three controls were identified.

All participants gave written informed consent at the time of recruitment, and the project was approved by the research ethics board at Umeå University (research authorization number 2009-1436-31).

2.4. Laboratory methods

We measured four kallikrein (KLK) markers—human kallikrein-related peptidase 2 (hK2) and total, free, and intact PSA—in cryopreserved blood samples from cases and controls. All laboratory analyses were conducted blind to outcome and case-control status. We measured total and free PSA with the dual-label DELFIA ProStatus assay (PerkinElmer, Turku, Finland) [6], calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards, in previously unthawed cryopreserved heparin anticoagulated blood plasma. Intact PSA and hK2 were measured using Fab(ab')2 fragments of the monoclonal capture antibodies to reduce the frequency of nonspecific assay interference [7].

2.5. Statistical methods

To estimate absolute risk, we used predictive mean matching to impute marker levels for men not selected as controls and for 16 men (1 man aged 50 yr and 15 men aged 60 yr) with metastasis who had missing samples. Statistical analyses were performed on the population level utilizing the measured and imputed values combined across 10 imputations using the Rubin rules. The four KLK markers were combined as previously described [8] into a statistical risk prediction model that gives

### Table 1 – Participant characteristics in the Va¨sterbotten Intervention Project

<table>
<thead>
<tr>
<th>Age 40 yr n = 17 086</th>
<th>Age 50 yr n = 17 837</th>
<th>Age 60 yr n = 15 634</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA, ng/ml, at ages 40, 50, and 60 yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent prostate cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 77 years</td>
<td>1.3 (0.9, 2.1)</td>
<td>2.0 (1.3, 3.3)</td>
</tr>
<tr>
<td>Subsequent distant metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 10 years</td>
<td>1.1 (0.7, 1.7)</td>
<td>1.2 (0.7, 2.1)</td>
</tr>
<tr>
<td>Controls with PSA measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 228</td>
<td>0.7 (0.5, 0.9)</td>
<td>0.8 (0.6, 1.2)</td>
</tr>
<tr>
<td>Controls with imputed PSA measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7 (0.5, 0.9)</td>
<td>0.8 (0.6, 1.2)</td>
<td>1.1 (0.7, 2.0)</td>
</tr>
</tbody>
</table>

PSA = prostate-specific antigen.

* A total of 12 men died from prostate cancer without documented metastasis. These were recorded as having metastasis on the date of death.
1 Age at baseline showing the number of men providing blood samples.
2 Number of men providing blood at ages 40, 50, and 60 yr later diagnosed with prostate cancer and with documented evidence of distant metastases.
3 Number of men providing blood at ages 40, 50, and 60 followed for 10, 15, and 20 yr.
the risk of any grade (or Gleason score ≥7) cancer at prostate biopsy. However, because the current study used anticoagulated blood plasma rather than serum, the model was adjusted using biopsy data from the UK Prostate Testing for Cancer and Treatment (ProtecT) study [9] that used blood plasma samples anticoagulated with ethylenediaminetetraacetic acid to predict Gleason score ≥7 (high-grade) cancer at 10-core prostate biopsy. The model was completed before it was applied to the VIP cohort [10], making the current study an external validation of a prespecified model. All analyses were conducted in Stata v.12 software (StataCorp, College Station, TX, USA).

3. Results

Table 1 shows the number of men in the VIP cohort who were aged 40, 50, and 60 yr at the time of the blood draw and PSA concentrations at those ages in men subsequently diagnosed with PCa and in men with documented evidence of distant metastases and their matched controls. It also shows the number of living men at risk of a PCa diagnosis or metastatic PCa at different durations of follow-up and the number of men with documented metastases. The VIP cohort included 12 542 men followed for >15 yr, 1423 men diagnosed with incident PCa, and 235 cases with documented evidence of distant PCa metastasis. Details on patient and tumor characteristics (including PSA level at time of diagnosis) are described in Supplementary Table 1. PSA concentrations at ages 40, 50, and 60 yr in controls were similar to previous population estimates in Sweden [11,12], Ireland [13], and the United States [14–16].

There were very few metastatic cases (n = 10) in men aged 40 yr at blood collection; further analyses are not presented in the primary text of this paper (Supplementary Table 2). For the older cohorts, as shown in Figure 1 and Table 2, there was a strong association between 15- to 20-yr risk of metastases and PSA, with a C-index of 0.816 (95% confidence interval [CI], 0.718–0.889) for PSA at age 50 and

![Image](https://via.placeholder.com/150)

**Fig. 1 – Risk of distant metastasis within 15 yr (dashed line) and 20 yr (solid line) by prostate-specific antigen (PSA). The four areas depicted in dark and light orange reflect the four quartiles of the population distribution of PSA levels. (A) Age 60 yr; (B) age 50 yr.**

**Table 2 – Risk of distant prostate cancer metastases by 15 and 20 yr of follow-up**

<table>
<thead>
<tr>
<th>PSA level, ng/ml</th>
<th>Absolute risk of metastases (95% CI)</th>
<th>Cumulative proportion of metastases, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15-yr risk</td>
<td>20-yr risk</td>
</tr>
<tr>
<td>Top decile</td>
<td>&gt;1.9</td>
<td>2.40 (1.47–3.70)</td>
</tr>
<tr>
<td>Top quartile</td>
<td>&gt;1.3</td>
<td>1.48 (0.99–2.12)</td>
</tr>
<tr>
<td>Second quartile</td>
<td>0.8–1.3</td>
<td>0.25 (0.08–0.67)</td>
</tr>
<tr>
<td>Third quartile</td>
<td>0.6–0.8</td>
<td>0.13 (0.02–0.54)</td>
</tr>
<tr>
<td>Bottom quartile</td>
<td>&lt;0.6</td>
<td>0.15 (0.03–0.47)</td>
</tr>
<tr>
<td>Below 63rd centile</td>
<td>&lt;1.0</td>
<td>0.14 (0.05–0.31)</td>
</tr>
<tr>
<td>Below median</td>
<td>&lt;0.8</td>
<td>0.14 (0.05–0.35)</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td>0.52 (0.37–0.72)</td>
</tr>
<tr>
<td>Top decile</td>
<td>&gt;3.8</td>
<td>9.33 (7.26–11.71)</td>
</tr>
<tr>
<td>Top quartile</td>
<td>&gt;2.1</td>
<td>5.28 (4.25–6.46)</td>
</tr>
<tr>
<td>Second quartile</td>
<td>1.2–2.1</td>
<td>1.55 (0.95–2.41)</td>
</tr>
<tr>
<td>Third quartile</td>
<td>0.7–1.2</td>
<td>0.59 (0.27–1.18)</td>
</tr>
<tr>
<td>Bottom quartile</td>
<td>&lt;0.7</td>
<td>0.26 (0.07–0.81)</td>
</tr>
<tr>
<td>Below median</td>
<td>&lt;1.2</td>
<td>0.44 (0.23–0.79)</td>
</tr>
<tr>
<td>Below 41st centile</td>
<td>&lt;1.0</td>
<td>0.43 (0.21–0.83)</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td>2.00 (1.66–2.39)</td>
</tr>
</tbody>
</table>

PSA = prostate-specific antigen.

* Cumulative proportions are given by cumulative quantile. For example, 85% of documented metastases occurred in men who had PSA in the top or second quartile at age 50 yr; 56% of metastases occurred in men in the top decile of PSA levels at age 60 yr.
0.847 (95% CI, 0.807–0.886) for PSA at age 60 (Supplementary Table 3). Most cases with metastasis were found among men whose PSA was above median for a decade or more before metastases were diagnosed (Supplementary Fig. 1; Supplementary Table 4). PSA measured at age 50 or 60 provided a wide separation of risk, with a 4- to 14-fold higher relative risk of metastases in men with PSA concentrations in the top quartile compared with those below the median (Table 2). As shown in Table 2, 69% of metastatic cases were documented in men with PSA in the top quartile at age 50 (>1.3 ng/ml); 74% of metastatic cases were documented in men with PSA in the top quartile at age 60 (>2.1 ng/ml). However, PSA levels below the median at ages 50–60 yr were associated with a very low risk of distant metastases. The 20-yr risk of metastasis for men with PSA ≤1.0 ng/ml at age 60 (close to the median) was <0.6% (Table 2). Despite the substantially elevated long-term risk of distant metastases associated with a PSA concentration in the top quartile or decile at age 50 or 60, the vast majority of these men remained metastasis free at 15–20 yr (Fig. 1; Supplementary Table 2 and 4).

We then examined whether a prespecified statistical model based on four KLK markers measured in the ProtecT study participants and developed to predict the risk of high-grade cancer at prostate biopsy [10] also could predict distant metastasis occurring 10–20 yr later (Supplementary Table 3). Although the model did not enhance discrimination of PSA in all men, it did so in men with PSA above the median at age 50 or 60. For instance, among men with PSA >2 ng/ml at age 50, discrimination was 0.751 for total PSA alone compared with 0.863 for the model (increase of 0.112; 95% CI, 0.040–0.097); for men with PSA >2 ng/ml at age 60, discrimination increased from 0.805 to 0.875 (0.070; 95% CI, 0.020–0.219); for men with PSA >2 ng/ml at age 60, discrimination increased from 0.805 to 0.875 (0.070; 95% CI, 0.020–0.219).

Given these results, we conducted a decision analysis evaluating the hypothetical clinical outcomes had the KLK marker–based model data been used to aid decisions about biopsy in the VIP cohort. Biopsying all men with PSA ≥3.0 ng/ml, the approach used in the randomized trial supporting PSA screening [1,2] would have resulted in a biopsy performed on 15.6% of men aged 60 yr. This rate would have been reduced by 38% (Fig. 2A) if biopsy was recommended only to those with ≥7.5% risk of high-grade cancer according to the model (Table 3; Supplementary Table 5). Among men aged 60 yr with PSA ≥3 ng/ml and <7.5% risk according to the model, the 15-yr risk of distant metastases remained low (0.99%) compared with the population average (2%). For men with PSA ≥2 ng/ml at age 50 (top decile of PSA levels at age 50), using ≥5% risk according to the model as the criterion for biopsy would lead to only 41% of these men undergoing a biopsy (Fig. 2B). Among all men aged 50 yr with PSA ≥2 ng/ml, those with <5% risk according to the model had a very low 15-yr risk (<0.5%) of distant metastasis (Table 3). Thus a substantial proportion of men with modestly increased PSA but low KLK risk scores identified by our screening strategy would be excluded from biopsy, and for these men, there is little risk of missing a lethal cancer even in the absence of frequent (e.g. biennial) follow-up.

### 4. Discussion

In this large representative cohort from Sweden, with >12 500 men followed for >15 yr and initially low rates of opportunistic PSA testing, PSA measured in cryopreserved blood collected at age 50 or 60 predicted metastasis at 15–20-yr follow-up. In the subset of men with modestly elevated PSA, a prespecified model based on a panel of four KLK markers increased the predictive discrimination of metastasis.

Risk stratification contributed by PSA was far greater than that reported for other risk factors such as race or family history [17]. Among men with modestly elevated PSA at age 50 or 60, the four KLK panel yielded C-indexes from 0.82 to 0.88 for the prediction of documented distant metastasis. This can be compared with discrimination close...
to 0.60 for the Gail model that is used clinically to determine eligibility for breast cancer chemoprevention [18].

Several long-term studies including a prospective observational study reported by Parkes et al [19] and others reviewed by Loeb et al [16] have found PSA to be highly prognostic of the long-term risk of aggressive PCa in unscreened men. The Malmö Preventive Project (MPP) [11,12] that involved blood samples taken from 1974 to 1986 with follow-up for metastasis and death through 2006 is most comparable with the current study. Although overall estimates of PCa risk are very similar between the studies, the C-index of PSA for metastasis was somewhat lower in the current study: 0.86 at 25 yr in VIP. This may be related to the panel could be exempted from biopsy and reassured that they would be unlikely to develop metastatic disease, even if PSA and the other KLK markers were not monitored every year.

Our findings strongly support a risk-stratified approach to screening and biopsy. In men aged 50 yr, the 15-yr risk of metastasis among those in the top decile for PSA was 3.15%, compared with biopsying all men with PSA ≥3 ng/ml, biopsying men with PSA ≥2 ng/ml and ≥10% risk from the panel would reduce biopsy rates by 45% but detect a similar number of men who would develop distant metastases within 10 yr (56 vs 57 per 10 000 men). Men with a modest PSA elevation but a low risk of high-grade cancer according to the panel could be exempted from biopsy and reassured that they would be unlikely to develop metastatic disease, even if PSA and the other KLK markers were not monitored every year.

Our results also replicated prior findings that the KLK markers measured in blood enhance the discrimination of malignant from benign PSA elevations [8,20]. Enormous efforts have been invested searching for biomarkers to be used with PSA to improve screening for PCa [21–25]. Although some markers are predictive of biopsy outcome, this is the first time markers have been shown to improve long-term prediction of distant metastasis, in this case with large increases in discrimination. These findings support the use of the KLK panel as a reflex test for biopsy in midlife among men with a modestly elevated PSA. For instance,
in earlier studies. Our findings are consistent with prior research demonstrating that men with a low PSA at age 60 have no mortality reduction from PSA screening but are at considerable risk of overdiagnosis [28]. This supports the calls to limit screening in such men.

5. Conclusions

We found that blood levels of PSA at ages 50 and 60 yr are prognostic of the long-term risk of metastatic PCs and that a panel of KLK markers is strongly predictive of distant metastasis documented many years later in men with a modestly elevated PSA. Our study has the following clinical implications. First, widespread PSA testing at age 40 cannot be justified. Second, screening can stop in men with PSA below the median (<1 ng/ml) at age ≥60 yr. Third, for men in their fifties, screening could focus mainly on those in the top decile of PSA (>1.9 ng/ml) because close to half of the subsequent cases of distant metastasis are found in this group; men with lower PSAs should still be screened but less intensively. Finally, four KLK markers measured in the blood can be used as a reflex test to aid biopsy decisions.

Author contributions: Hans Lilja had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Stattin, Vickers, Lilja.

Acquisition of data: Stattin, Lilja, R. Johansson, Granfors, M. Johansson, Hallmans.


Drafting of the manuscript: Stattin, Lilja, Vickers.

Critical revision of the manuscript for important intellectual content: Stattin, Lilja, Vickers.

Statistical analysis: Vickers, Sjoberg.

Obtaining funding: Lilja, Vickers, Scardino, Stattin.

Administrative, technical, or material support: Lilja, Scardino, Pettersson.


Other (specify): Scardino advised on the overall study concept and clinical interpretation.

Financial disclosures: Hans Lilja certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received or pending), are the following: Hans Lilja holds patents for free prostate-specific antigen, human kallikrein-related peptidase 2, and intact prostate-specific antigen assays and is named, along with Andrew J. Vickers, on a patent application for a statistical method to detect prostate cancer. The method was commercialized by OPKO. Hans Lilja, Andrew J. Vickers, Kim Pettersson, and Peter T. Scardino will receive royalties from any sales of the test.

Funding/Support and role of the sponsor: This work was supported in part by the National Cancer Institute at the National Institutes of Health (R33 CA127768 to Hans Lilja, R01 CA160816 to Hans Lilja and Andrew J. Vickers, P50 CA092629 to Peter R. Scardino and Andrew J. Vickers, and P30 CA08748 to Andrew J. Vickers); the Sidney Kimmel Center for Prostate and Urologic Cancers; David H. Koch through the Prostate and Urologic Cancers; David H. Koch through the Prostate Cancer Foundation to Peter T. Scardino, Andrew J. Vickers, and Hans Lilja; the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Program to Hans Lilja; Swedish Cancer Society (projects no. 11-0624 and 14-0722 to Hans Lilja and 11-0471 to Pär Stattin); and Fundación Federico SA to Hans Lilja. The funding sources did not have any role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

Acknowledgments: We thank Åsa Ågren, Västerbotten Intervention Project, Umeå, Sweden, for data management; Britt-Inger Dahlin, research nurse, Department of Urology, Umeå University Hospital (Sweden) for chart review; and the Västerbotten County (Sweden) for providing the blood samples. We also thank Gun-Britt Eriksson, Mona Hassan Al-Battat, and AnnaPeri Erlandsson for expert assistance with immunoassay measurements of the blood samples at the Wallenberg Research Laboratories at Lund University, Malmö, Sweden. All participants gave written informed consent at the time of recruitment, and the project was approved by the Research Ethics Board at Umeå University (research authorization number 2009-1436-31).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.eururo.2015.01.009.

References


